stockrowGlobus Medical, Inc.
GMED Healthcare Medical Devices
Globus Medical, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.9 billion, up 16.7% from fiscal 2024.
- Revenue
- −0.69%
- EPS
- +19.3%
- Free cash flow
- +10.1%
Quarter to September 2026, against a year earlier
Follow GMED
Alert me
Globus Medical, Inc. (GMED) Shares outstanding
Globus Medical, Inc.'s shares outstanding at the end of fiscal 2025 was $137.1M, unchanged from fiscal 2024. At the end of the quarter to 30 September 2026 it was $136.0M. Over the past ten years it has ranged from $96.1M (fiscal 2015) to $137.9M (fiscal 2024); the current reading is higher than 91% of that period. Globus Medical, Inc. ranks 24th of 147 Medical Devices companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $137.1M | (0.59%) |
| FY2024 | $137.9M | 20.27% |
| FY2023 | $114.6M | 11.68% |
| FY2022 | $102.6M | (0.95%) |
| FY2021 | $103.6M | 2.63% |
| FY2020 | $101.0M | (1.01%) |
| FY2019 | $102.0M | 0.67% |
| FY2018 | $101.3M | 3.50% |
| FY2017 | $97.9M | 1.51% |
| FY2016 | $96.4M | 0.37% |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Sep 2026 | $136.0M | (1.00%) |
| Jun 2026 | $137.4M | (0.58%) |
| Mar 2026 | $138.2M | 0.83% |
| Dec 2025 | $137.1M | 1.23% |
| 43 more quarters | Free account |
Against its own ten years
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| SNN Smith & Nephew SNATS, Inc. compare | $449.4M |
| BRKR Bruker Corporation compare | $152.5M |
| GMED Globus Medical, Inc. | $136.0M |
| TXG 10x Genomics compare | $130.0M |
| PODD Insulet Corporation compare | $69.5M |
| GKOS Glaukos Corporation compare | $61.2M |
| PEN Penumbra, Inc. compare | $39.6M |
| BIO.B Bio-Rad Laboratories, Inc. compare | $26.9M |
| BIO Bio-Rad Laboratories, Inc. compare | $26.9M |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item
More on GMED
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement